Compare VERA & FSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VERA | FSK |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.0B |
| IPO Year | 2021 | 2008 |
| Metric | VERA | FSK |
|---|---|---|
| Price | $30.01 | $11.44 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 8 |
| Target Price | ★ $81.30 | $13.19 |
| AVG Volume (30 Days) | 2.0M | ★ 2.3M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 18.82% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $472.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.07 | $9.72 |
| 52 Week High | $56.05 | $20.41 |
| Indicator | VERA | FSK |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 59.40 |
| Support Level | N/A | $10.41 |
| Resistance Level | N/A | $11.22 |
| Average True Range (ATR) | 0.00 | 0.28 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 99.60 |
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.